Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 23

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

AbbVie Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (unaudited)

Three months endedSeptember 30,Nine months endedSeptember 30,(in millions, except per share data)2025202420252024Net revenues$15,776 $14,460 $44,542 $41,232 Cost of products sold5,304 4,212 13,652 12,508 Selling, general and administrative3,569 4,205 10,115 10,897 Research and development2,319 2,130 6,517 6,017 Acquired IPR&D and milestones2,680 82 3,751 1,183 Other operating income— — (24)— Total operating costs and expenses13,872 10,629 34,011 30,605 Operating earnings1,904 3,831 10,531 10,627 Interest expense, net667 591 1,972 1,550 Net foreign exchange loss (gain)20 (3)47 2 Other expense, net503 1,159 4,583 3,090 Earnings before income tax expense714 2,084 3,929 5,985 Income tax expense526 520 1,511 1,676 Net earnings188 1,564 2,418 4,309 Net earnings attributable to noncontrolling interest2 3 8 9 Net earnings attributable to AbbVie Inc.$186 $1,561 $2,410 $4,300 Per share dataBasic earnings per share attributable to AbbVie Inc.$0.10 $0.88 $1.35 $2.41 Diluted earnings per share attributable to AbbVie Inc.$0.10 $0.88 $1.34 $2.41 Weighted-average basic shares outstanding1,769 1,769 1,769 1,769 Weighted-average diluted shares outstanding1,772 1,772 1,772 1,772 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 1

AbbVie Inc. and Subs